Evotec SE has announced substantial progress in its strategic research collaboration with Bristol Myers Squibb, which aims to develop a high-value molecular glue-based pipeline for addressing unmet medical needs. Evotec will receive payments totaling $75 million based on performance-based and program-based achievements. The collaboration, initiated in 2018, integrates Evotec’s advanced multi-omics screening capabilities, AI-supported data analytics, and drug design expertise with Bristol Myer...